Corticotropin-releasing factor (CRF) can be considered a very important hormone or a chemical mediator. It works closely with other systems to regulate the manner through which the body may respond to stress. Thus it affects many biological processes associated with stress. Dysfunction of this system has also been correlated with various diseases such as major depression, anxiety, drug addiction and eating disorders. Rationally, this means that interfering with binding of CRF to its intended receptors can be an attractive target for drug design aiming at developing new medications for many ailments that are associated with stress such as depression, anxiety and stress-induced relapse in drug addiction. Hundreds of accounts of small molecule antagonists have appeared in the literature and the preclinical and clinical pharmacology have been reported for many of these agents. Several classes of small molecule CRF receptor antagonists which belong to the non-peptide class have been developed with many being widely used for research purposes. Currently several major pharmaceutical companies are pursuing development of small non-peptide CRF1 receptor antagonists. In this review article we explain the importance of development of non-peptide CRF antagonists and their clinical relevance with emphasis on those members that showed great promise or those that were advanced to clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1874467209666161101144155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study.
RSC Med Chem
December 2024
Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara 44121 Ferrara Italy
The N/OFQ-NOP receptor is a fascinating peptidergic system with the potential to be exploited for the development of analgesic drugs devoid of side effects associated with classical opioid signalling modulation. To date, up to four X-ray and cryo-EM structures of the NOP receptor in complex with the endogenous peptide agonist N/OFQ and three small molecule antagonists have been solved and released. Despite the available structural information, the details of selective small molecule agonist binding to the NOP receptor in the active state remain elusive.
View Article and Find Full Text PDFEnhanced motivated behavior mediated by pharmacological targeting of the FGF14/Na1.6 complex in nucleus accumbens neurons.
Nat Commun
January 2025
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX, USA.
Article Synopsis
- Protein/protein interactions (PPI) are important for brain functions, but their use as drug targets for brain disorders is not fully explored.
- A small molecule called compound 1028 has been identified that targets the FGF14/Na1.6 PPI and affects the channel's activity, resulting in increased excitability of neurons.
- Administering compound 1028 can enhance motivation under challenging conditions, and its effects are linked to changes in dopamine levels in the brain, suggesting a new way to impact behaviors related to neuropsychiatric disorders.
Conserved and Unique Roles of bHLH-PAS Transcription Factors in Insects - From Clock to Hormone Reception.
J Mol Biol
October 2023
Institute of Entomology, Biology Center of the Czech Academy of Sciences, Ceske Budejovice 37005, Czech Republic. Electronic address:
A dozen bHLH-PAS transcription factors have evolved since the dawn of the animal kingdom; nine of them have mutual orthologs between arthropods and vertebrates. These proteins are master regulators in a range of developmental processes from organogenesis, nervous system formation and functioning, to cell fate decisions defining identity of limbs or photoreceptors for color vision. Among the functionally best conserved are bHLH-PAS proteins acting in the animal circadian clock.
View Article and Find Full Text PDFNovel non-peptide uracil-derived human gonadotropin-releasing hormone receptor antagonists.
Eur J Med Chem
December 2024
Department of Pharmaceutical Sciences, University of Milan, Milan, Italy.
Gonadotropin-releasing hormone (GnRH) is the main regulator of the reproductive system, acting on gonadotropic cells by binding to the GnRH1 receptor (GnRH1R). Traditionally, therapies targeting this receptor have relied on peptide modulators, which required subcutaneous or intramuscular injections. Due to the limitations of the parenteral administrations, there is a growing interest in developing oral small molecule modulators of GnRH1R as more convenient therapeutic alternatives.
View Article and Find Full Text PDFIsoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs.
Biochem Pharmacol
November 2024
Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia; ARC Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville 3052, Victoria, Australia. Electronic address:
Class B1 G protein-coupled receptors (GPCRs) are peptide hormone receptors and well validated therapeutic targets, however development of non-peptide drugs targeting this class of receptors is challenging. Recently, a series of isoquinoline-based derivates were reported in the patent literature as allosteric ligands for the glucagon receptor subfamily, and two compounds, LSN3451217 and LSN3556672, were used to facilitate structural studies with the glucagon-like peptide-1 receptor (GLP-1R) and glucose dependent insulinotropic peptide receptor (GIPR) bound to orthosteric agonists. Here we pharmacologically characterized stereoisomers of LSN3451217 and LSN3556672, across the class B1 GPCR family.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!